Walton Marc K, Powers John H, Hobart Jeremy, Patrick Donald, Marquis Patrick, Vamvakas Spiros, Isaac Maria, Molsen Elizabeth, Cano Stefan, Burke Laurie B
Janssen Research and Development, Titusville, NJ, USA.
Leidos Biomedical Research in support of the Division of Clinical Research, National Institutes of Health, Bethesda, MD, USA.
Value Health. 2015 Sep;18(6):741-52. doi: 10.1016/j.jval.2015.08.006. Epub 2015 Aug 24.
An outcome assessment, the patient assessment used in an endpoint, is the measuring instrument that provides a rating or score (categorical or continuous) that is intended to represent some aspect of the patient's health status. Outcome assessments are used to define efficacy endpoints when developing a therapy for a disease or condition. Most efficacy endpoints are based on specified clinical assessments of patients. When clinical assessments are used as clinical trial outcomes, they are called clinical outcome assessments (COAs). COAs include any assessment that may be influenced by human choices, judgment, or motivation. COAs must be well-defined and possess adequate measurement properties to demonstrate (directly or indirectly) the benefits of a treatment. In contrast, a biomarker assessment is one that is subject to little, if any, patient motivational or rater judgmental influence. This is the first of two reports by the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force. This report provides foundational definitions important for an understanding of COA measurement principles. The foundation provided in this report includes what it means to demonstrate a beneficial effect, how assessments of patients relate to the objective of showing a treatment's benefit, and how these assessments are used in clinical trial endpoints. In addition, this report describes intrinsic attributes of patient assessments and clinical trial factors that can affect the properties of the measurements. These factors should be considered when developing or refining assessments. These considerations will aid investigators designing trials in their choice of using an existing assessment or developing a new outcome assessment. Although the focus of this report is on the development of a new COA to define endpoints in a clinical trial, these principles may be applied more generally. A critical element in appraising or developing a COA is to describe the treatment's intended benefit as an effect on a clearly identified aspect of how a patient feels or functions. This aspect must have importance to the patient and be part of the patient's typical life. This meaningful health aspect can be measured directly or measured indirectly when it is impractical to evaluate it directly or when it is difficult to measure. For indirect measurement, a concept of interest (COI) can be identified. The COI must be related to how a patient feels or functions. Procedures are then developed to measure the COI. The relationship of these measurements with how a patient feels or functions in the intended setting and manner of use of the COA (the context of use) could then be defined. A COA has identifiable attributes or characteristics that affect the measurement properties of the COA when used in endpoints. One of these features is whether judgment can influence the measurement, and if so, whose judgment. This attribute defines four categories of COAs: patient reported outcomes, clinician reported outcomes, observer reported outcomes, and performance outcomes. A full description as well as explanation of other important COA features is included in this report. The information in this report should aid in the development, refinement, and standardization of COAs, and, ultimately, improve their measurement properties.
结局评估是在终点使用的患者评估,是一种测量工具,可提供旨在代表患者健康状况某些方面的评分或分数(分类或连续)。在为疾病或病症开发治疗方法时,结局评估用于定义疗效终点。大多数疗效终点基于对患者的特定临床评估。当临床评估用作临床试验结局时,它们被称为临床结局评估(COA)。COA包括任何可能受人为选择、判断或动机影响的评估。COA必须定义明确并具有足够的测量属性,以(直接或间接)证明治疗的益处。相比之下,生物标志物评估几乎不受患者动机或评估者判断影响(如果有影响的话)。这是ISPOR临床结局评估——结局研究新兴良好实践特别工作组的两份报告中的第一份。本报告提供了对于理解COA测量原则很重要的基础定义。本报告提供的基础包括证明有益效果意味着什么、对患者的评估如何与显示治疗益处的目标相关联,以及这些评估如何用于临床试验终点。此外,本报告描述了患者评估的内在属性以及可能影响测量属性的临床试验因素。在开发或完善评估时应考虑这些因素。这些考虑将有助于设计试验的研究人员在选择使用现有评估或开发新的结局评估时做出决策。尽管本报告的重点是开发用于定义临床试验终点的新COA,但这些原则可能更广泛地适用。评估或开发COA的一个关键要素是将治疗的预期益处描述为对患者感受或功能的明确确定方面的影响。这个方面必须对患者具有重要性,并且是患者日常生活的一部分。这个有意义的健康方面可以直接测量,或者在直接评估不切实际或难以测量时进行间接测量。对于间接测量,可以确定一个感兴趣的概念(COI)。COI必须与患者的感受或功能相关。然后制定测量COI的程序。然后可以定义这些测量与患者在COA的预期使用环境和使用方式下(使用背景)的感受或功能之间的关系。COA具有可识别的属性或特征,这些属性或特征在用于终点时会影响COA的测量属性。其中一个特征是判断是否会影响测量,如果是,是谁的判断。这个属性定义了四类COA:患者报告结局、临床医生报告结局、观察者报告结局和性能结局。本报告包括对其他重要COA特征的完整描述和解释。本报告中的信息应有助于COA的开发、完善和标准化,并最终改善其测量属性。